Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 11/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.51 |
| ▸ | JAK2 | O60674 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | JAK1 | P23458 | 3/20 | 0.50 |
| ▸ | TYK2 | P29597 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | JAK3 | P52333 | 3/20 | 0.50 |
| ▸ | SRC | P12931 | 3/20 | 0.50 |
| ▸ | GSK3B | P49841 | 3/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173272 | 0.87 | AKR1B1 (0.39) | AURKANTRK1AURKBJAK2CYP3A4 | |
| SCHEMBL178180 | 0.86 | AURKA (0.40) | AURKANTRK1AURKBJAK2CYP3A4 | |
| SCHEMBL174204 | 0.85 | AURKA (0.48) | AURKANTRK1AURKBJAK2CYP3A4 | |
| SCHEMBL254830 | 0.82 | AKR1B1 (0.38) | AURKANTRK1AURKB | |
| SCHEMBL174514 | 0.79 | AURKA (0.52) | AURKANTRK1AURKBJAK2CYP3A4 | |
| SCHEMBL15366689 | 0.78 | SOD1 (0.48) | AURKANTRK1AURKBSRCGSK3B | |
| SCHEMBL159667 | 0.77 | JAK2 (0.43) | AURKANTRK1JAK2JAK1JAK3 | |
| SCHEMBL169394 | 0.77 | NTRK1 (0.55) | AURKANTRK1AURKBJAK2CYP3A4 | |
| SCHEMBL255633 | 0.76 | NTRK1 (0.52) | AURKANTRK1AURKBJAK2CYP3A4 | |
| SCHEMBL174448 | 0.76 | HTR6 (0.38) | CYP3A4CYP2C9CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2663553-B1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | AMBIT BIOSCIENCES CORP (US) | 2015-08-26 | — | — | EP | claimed |
| US-20130296363-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-07 | — | — | US | claimed |
| EP-2663553-B1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | AMBIT BIOSCIENCES CORP (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2663553-A2 | QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20130296363-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296363-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296363-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2012030944-A2 | QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030944-A2 | QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296363-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | JAK3, JAK2, JAK1 | AURKA 587/4885NTRK1 2263/4885AURKB 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.